Research progress of immune checkpoint inhibitors in ovarian cancer DOI Creative Commons

Lingli Zhao,

Yanhong Zhai,

Gaoli Niu

и другие.

Exploration of Immunology, Год журнала: 2024, Номер unknown, С. 853 - 870

Опубликована: Дек. 18, 2024

Ovarian cancer is the deadliest malignant tumor in female reproductive system. Despite advancements standard treatments such as debulking surgery and platinum-based chemotherapy, overall survival rate remains low. The emergence of targeted therapies, including Poly(ADP-ribose) polymerase (PARP) inhibitors anti-angiogenic agents, has provided new avenues for treatment. However, drug resistance disease heterogeneity continue to pose significant challenges. Immune checkpoint (ICIs), an emerging therapeutic approach, primarily target programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways restore anti-tumor immune responses. Although ICIs have shown efficacy other malignancies, their effectiveness ovarian limited, with a response only 10–15% monotherapy. Recent studies focused on combining or PARP enhance outcomes. This article reviews progress cancer, monotherapy combination treatment strategies, explores targets strategies aimed at improving patient prognosis achieving personalized By gaining deeper understanding microenvironment its evasion mechanisms, there hope developing more effective options future, ultimately rates quality life patients.

Язык: Английский

An Acceptor–Donor–Acceptor Structured Nano‐Aggregate for NIR‐Triggered Interventional Photoimmunotherapy of Cervical Cancer DOI

Gaoli Niu,

Xingqi Bi,

Yong Kang

и другие.

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Авг. 3, 2024

Compared with conventional therapies, photoimmunotherapy offers precise targeted cancer treatment minimal damage to healthy tissues and reduced side effects, but its efficacy may be limited by shallow light penetration the potential for tumor resistance. Here, an acceptor-donor-acceptor (A-D-A)-structured nanoaggregate is developed dual phototherapy, including photodynamic therapy (PDT) photothermal (PTT), triggered single near-infrared (NIR) light. Benefiting from strong intramolecular charge transfer (ICT), A-D-A-structured nanoaggregates exhibit broad absorption extending NIR region effectively suppressed fluorescence, which enables deep efficient conversion (η = 67.94%). A suitable HOMO-LUMO distribution facilitates sufficient intersystem crossing (ISC) convert ground-state oxygen (

Язык: Английский

Процитировано

11
Biomimetic Dual‐Driven Heterojunction Nanomotors for Targeted Catalytic Immunotherapy of Glioblastoma DOI Open Access
Jiamin Ye,

Yueyue Fan,

Yong Kang

и другие.

Advanced Functional Materials, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 9, 2024

Abstract The existence of the blood–brain barrier (BBB) and characteristics immunosuppressive microenvironment in glioblastoma (GBM) present significant challenges for targeted GBM therapy. To address this, a biomimetic hybrid cell membrane‐modified dual‐driven heterojunction nanomotor (HM@MnO 2 ‐AuNR‐SiO ) is proposed treatment. These nanomotors are designed to bypass BBB target glioma regions by mimicking surface macrophage membranes. More importantly, MnO structure enables propulsion through near‐infrared‐II (NIR‐II) light oxygen bubbles, allowing effective treatment at deep tumor sites. Meanwhile, plasmonic AuNR‐MnO heterostructure facilitates separation electron–hole pairs generates reactive species (ROS), inducing immunogenic death under NIR‐II laser irradiation. Furthermore, reacts release Mn 2+ ions, activating cGAS‐STING pathway enhancing antitumor immunity. In vitro vivo experiments demonstrate that these achieve active targeting infiltration, promoting M1 polarization, dendritic maturation, effector T‐cell activation, thereby catalysis immunotherapy ROS production STING activation.

Язык: Английский

Процитировано

6
Quinoidal Semiconductor Nanoparticles for NIR‐II Photoacoustic Imaging and Photoimmunotherapy of Cancer DOI Open Access

Gaoli Niu,

Guangkun Song,

Yong Kang

и другие.

Advanced Materials, Год журнала: 2024, Номер unknown

Опубликована: Дек. 18, 2024

Photoagents with ultra-high near-infrared II (NIR-II) light energy conversion efficiency hold great promise in tumor phototherapy due to their ability penetrate deeper tissues and minimize damage surrounding healthy cells. However, the development of NIR-II photoagents remain challenging. In this study, an all-fused-ring quinoidal acceptor-donor-acceptor (A-D-A) molecule, SKCN, a BTP core is synthesized, nanoparticles named FA-SNPs are prepared. The unique structure enhances π-electron delocalization bond length uniformity, significantly reducing bandgap resulting strong absorption, high molar extinction coefficient, photothermal 75.14%. Enhanced molecular rigidity also facilitates efficient transfer oxygen, boosting reactive oxygen species generation. By incorporating immunomodulator R848, FA-SRNPs further developed, effectively modulating immune microenvironment by Tregs M-MDSCs infiltration, promoting dendritic cell maturation, M1 macrophage polarization, activating CD8+ T cells NK Comprehensive studies using orthotopic ovarian cancer models demonstrated targeting, photoacoustic imaging capabilities, significant suppression metastasis inhibition, showing excellent therapeutic efficacy breast model. This study provides evidence for potential application A-D-A molecules photoimmunotherapy.

Язык: Английский

Процитировано

4
In situ vaccine “seeds” for enhancing cancer immunotherapy by exploiting apoptosis-associated morphological changes DOI
Binghua Wang,

Rong Guo,

Fujun Qiu

и другие.

Journal of Controlled Release, Год журнала: 2025, Номер 379, С. 757 - 767

Опубликована: Янв. 25, 2025

Язык: Английский

Процитировано

0
Recent advances in DNA nanotechnology for cancer detection and therapy: A review DOI

Donya Esmaeilpour,

Matineh Ghomi, Ehsan Nazarzadeh Zare‬

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 142136 - 142136

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology DOI Creative Commons
Shuang Ma, Ying Lü,

S.J. Sui

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 2, 2025

The intricate interaction between skeletal muscle biomechanics, the tumor microenvironment, and immunotherapy constitutes a pivotal research focus oncology. This work provides comprehensive review of methodologies for evaluating including handheld dynamometry, advanced imaging techniques, electrical impedance myography, elastography, single-fiber experiments to assess quality performance. Furthermore, it elucidates mechanisms, applications, limitations various modalities, immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, combined chemoimmunotherapy, while examining their effects on function systemic responses. Key findings indicate that although is effective in augmenting antitumor immunity, frequently induces muscle-related adverse such as weakness, fatigue, or damage, primarily mediated by cytokine release activation. underscores significance niches within microenvironment influencing treatment outcomes proposes strategies optimize therapy through personalized regimens combinatorial approaches. highlights need further formation interactions muscle-tumor. Our crucial advancing efficacy immunotherapy, reducing effects, ultimately improving survival rates life patients with cancer.

Язык: Английский

Процитировано

0
Research progress of immune checkpoint inhibitors in ovarian cancer DOI Creative Commons

Lingli Zhao,

Yanhong Zhai,

Gaoli Niu

и другие.

Exploration of Immunology, Год журнала: 2024, Номер unknown, С. 853 - 870

Опубликована: Дек. 18, 2024

Ovarian cancer is the deadliest malignant tumor in female reproductive system. Despite advancements standard treatments such as debulking surgery and platinum-based chemotherapy, overall survival rate remains low. The emergence of targeted therapies, including Poly(ADP-ribose) polymerase (PARP) inhibitors anti-angiogenic agents, has provided new avenues for treatment. However, drug resistance disease heterogeneity continue to pose significant challenges. Immune checkpoint (ICIs), an emerging therapeutic approach, primarily target programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways restore anti-tumor immune responses. Although ICIs have shown efficacy other malignancies, their effectiveness ovarian limited, with a response only 10–15% monotherapy. Recent studies focused on combining or PARP enhance outcomes. This article reviews progress cancer, monotherapy combination treatment strategies, explores targets strategies aimed at improving patient prognosis achieving personalized By gaining deeper understanding microenvironment its evasion mechanisms, there hope developing more effective options future, ultimately rates quality life patients.

Язык: Английский

Процитировано

0